<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085020</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000367118</org_study_id>
    <secondary_id>UCLA-0305039</secondary_id>
    <secondary_id>GSK-EGF10023</secondary_id>
    <nct_id>NCT00085020</nct_id>
  </id_info>
  <brief_title>GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu</brief_title>
  <official_title>A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination With Trastuzumab [Herceptin†]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: GW572016 may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      their growth. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either&#xD;
      kill them or deliver tumor-killing substances to them without harming normal cells. Giving&#xD;
      GW572016 with trastuzumab may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of GW572016 when given&#xD;
      together with trastuzumab in treating patients with metastatic breast cancer that&#xD;
      overexpresses HER2/neu.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the optimally tolerated regimen of GW572016 when administered with trastuzumab&#xD;
           (Herceptin^®) in patients with metastatic breast cancer that overexpresses HER2/neu.&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the pharmacokinetic parameters of this regimen in these patients.&#xD;
&#xD;
        -  Determine the clinical response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter, dose-escalation study of GW572016.&#xD;
&#xD;
      Patients receive oral GW572016 once daily on days 1-28 and trastuzumab (Herceptin^®) IV over&#xD;
      90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of GW572016 until the optimally tolerated&#xD;
      regimen (OTR) is determined. The OTR is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose-limiting toxicity. Once the OTR is determined, 10-18 additional&#xD;
      patients are entered and treated at the OTR.&#xD;
&#xD;
      Patients are followed at 28 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-35 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">13</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib ditosylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  HER2/neu overexpression (2+ or 3+) confirmed by immunohistochemistry and/or HER2 gene&#xD;
             amplification by fluorescence in situ hybridization&#xD;
&#xD;
          -  Brain metastases treated by surgery and/or radiotherapy allowed provided the following&#xD;
             criteria are met:&#xD;
&#xD;
               -  Neurologic status stable 2 weeks after discontinuing dexamethasone&#xD;
&#xD;
               -  No concurrent anticonvulsants that induce metabolism (e.g., phenytoin,&#xD;
                  carbamazepine, or phenobarbital)&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
          -  Life expectancy, At least 12 weeks&#xD;
&#xD;
          -  Hematopoietic&#xD;
&#xD;
               -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  AST and ALT ≤ 3 times upper limit of normal (ULN) (5 times ULN if patient has&#xD;
                  liver metastases)&#xD;
&#xD;
               -  Bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
               -  Creatinine clearance &gt; 30 mL/min&#xD;
&#xD;
          -  Cardiovascular&#xD;
&#xD;
               -  LVEF &gt; 50%&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 weeks after study&#xD;
             participation&#xD;
&#xD;
          -  Adequate venous access&#xD;
&#xD;
          -  Able to swallow and retain oral medication&#xD;
&#xD;
          -  Prior adjuvant/neoadjuvant chemotherapy allowed&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin.&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  More than 28 days since prior participation in another investigational study&#xD;
&#xD;
          -  More than 28 days since prior investigational drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  extensive tumor, pleural effusions, or parenchymal masses) resulting in dyspnea at&#xD;
             rest&#xD;
&#xD;
          -  uncontrolled brain metastases or leptomeningeal disease&#xD;
&#xD;
          -  prior myocardial infarction&#xD;
&#xD;
          -  pre-existing cardiac dysfunction (e.g., congestive heart failure)&#xD;
&#xD;
          -  clinically significant cardiac disease&#xD;
&#xD;
          -  angina pectoris&#xD;
&#xD;
          -  symptomatic intrinsic pulmonary disease (e.g., asthma or chronic obstructive pulmonary&#xD;
             disease) resulting in dyspnea at rest&#xD;
&#xD;
          -  pregnant or nursing&#xD;
&#xD;
          -  active infection&#xD;
&#xD;
          -  known hypersensitivity to Chinese Hamster Ovary cell proteins or any component of this&#xD;
             product&#xD;
&#xD;
          -  known immediate or delayed hypersensitivity reaction or idiosyncrasy to products of&#xD;
             similar chemical composition as study drug&#xD;
&#xD;
          -  known contraindications to trastuzumab (Herceptin^®)&#xD;
&#xD;
          -  malabsorption syndrome&#xD;
&#xD;
          -  disease significantly affecting gastrointestinal function&#xD;
&#xD;
          -  psychiatric disorder that would preclude study compliance&#xD;
&#xD;
          -  other serious illness or condition&#xD;
&#xD;
          -  concurrent biologic therapy&#xD;
&#xD;
          -  prior cumulative dose of doxorubicin &gt; 400 mg/m^2 (including liposomal doxorubicin)&#xD;
&#xD;
          -  concurrent hormonal therapy*&#xD;
&#xD;
          -  concurrent glucocorticoids&#xD;
&#xD;
          -  concurrent radiotherapy&#xD;
&#xD;
          -  prior major resection of the stomach or small bowel that could affect absorption of&#xD;
             GW572016&#xD;
&#xD;
          -  concurrent cytotoxic therapy&#xD;
&#xD;
          -  other concurrent anticancer therapy&#xD;
&#xD;
          -  other concurrent investigational drugs during and for 28 days after study treatment&#xD;
&#xD;
          -  concurrent administration of any of the following medications or substances:&#xD;
&#xD;
          -  Antibiotics&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Troleandomycin&#xD;
&#xD;
               -  Ciprofloxacin&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Norfloxacin&#xD;
&#xD;
               -  Rifabutin&#xD;
&#xD;
          -  HIV antivirals&#xD;
&#xD;
               -  Delaviridine&#xD;
&#xD;
               -  Indinavir&#xD;
&#xD;
               -  Nelfinavir&#xD;
&#xD;
               -  Ritonavir&#xD;
&#xD;
               -  Saquinavir&#xD;
&#xD;
               -  Efavirenz&#xD;
&#xD;
               -  Nevirapine&#xD;
&#xD;
               -  Amprenavir&#xD;
&#xD;
               -  Lopinavir&#xD;
&#xD;
          -  Anticonvulsants&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
          -  Antidepressants&#xD;
&#xD;
               -  Fluoxetine&#xD;
&#xD;
               -  Nefazodone&#xD;
&#xD;
               -  Fluvoxamine&#xD;
&#xD;
          -  Antifungals&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Fluconazole&#xD;
&#xD;
               -  Voriconazole&#xD;
&#xD;
          -  Antacids (within 1 hour before and after study drug administration)&#xD;
&#xD;
          -  Cimetidine&#xD;
&#xD;
          -  Amiodarone&#xD;
&#xD;
          -  Diltiazem&#xD;
&#xD;
          -  Pioglitazone&#xD;
&#xD;
          -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
          -  Grapefruit or grapefruit juice&#xD;
&#xD;
          -  Rifabutin&#xD;
&#xD;
          -  Diethyldithiocarbamate&#xD;
&#xD;
          -  Gestodene&#xD;
&#xD;
          -  Mifepristone&#xD;
&#xD;
          -  Modafinil&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D. Pegram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Storniolo AM, Burris HA III, Overmoyer B, et al.: A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-1040, 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Burris III HA, Storniolo AM, Overmoyer EA, et al.: A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. [Abstract] Breast Cancer Res Treat 88 (1): A-3043, 2004.</citation>
  </results_reference>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

